《大行报告》花旗:融创中国(01918.HK)去年业绩全方位略胜预期
花旗发表研究报告指,融创中国(01918.HK)去年度业绩略胜预期,纯利按年增长37%,核心盈利增长11.8%。
融创管理层在业绩会上透露,按当局对内房融资管控的「三道红线」措施,公司将在明年提前完成最後一个指标要求,负债杠杆得以下降。花旗预料,融创拥有强劲资产负债表,目前已达到当局要求的「黄档」,认为去年稳健的业绩反映公司持续降负债的成效。
该行指出,融创今年首两个月销售表现理想,合约销售额按年增长1.22倍,今年全年可售资源亦按年增加11%至9,100亿元人民币,予「买入」评级,目标价46.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.